The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity - PubMed (original) (raw)
. 2017 Jul 19;8(7):1448-1454.
doi: 10.1021/acschemneuro.7b00027. Epub 2017 Apr 4.
Affiliations
- PMID: 28362078
- DOI: 10.1021/acschemneuro.7b00027
The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity
Barbara Costa et al. ACS Chem Neurosci. 2017.
Abstract
The low binding affinity of the approved anxiolytic drug etifoxine (Stresam) at the steroidogenic 18 kDa translocator protein (TSPO) has questioned the specific contribution of this protein in mediating the etifoxine neurosteroidogenic efficacy. Residence time (RT) at the binding site of the classical TSPO ligand PK11195 is emerging as a relevant neurosteroidogenic efficacy measure rather than the binding affinity. Here etifoxine was evaluated for (i) the in vitro neurosteroidogenic activity in comparison to poorly neurosteroidogenic reference TSPO ligands (PK11195 and Ro5-4864) and (ii) the affinity and RT at [3H]PK11195 and [3H]Ro5-4864 binding sites in rat kidney membranes. Etifoxine shows (i) high neurosteroidogenic efficacy and (ii) low affinity/short RT at the [3H]PK11195 site and low affinity/long RT at the [3H]Ro5-4864 site, at which etifoxine competitively bound. These findings suggest that the long RT of etifoxine at the Ro5-4864 binding site could account for its high neurosteroidogenic efficacy.
Keywords: Etifoxine; anxiolytic effect; kinetic binding parameters; neurosteroidogenic efficacy; residence time.
Similar articles
- Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: Pharmacodynamic studies.
Liere P, Pianos A, Oudinet JP, Schumacher M, Akwa Y. Liere P, et al. Psychoneuroendocrinology. 2017 Sep;83:122-134. doi: 10.1016/j.psyneuen.2017.05.022. Epub 2017 Jun 3. Psychoneuroendocrinology. 2017. PMID: 28609670 - TSPO ligand residence time: a new parameter to predict compound neurosteroidogenic efficacy.
Costa B, Da Pozzo E, Giacomelli C, Barresi E, Taliani S, Da Settimo F, Martini C. Costa B, et al. Sci Rep. 2016 Jan 11;6:18164. doi: 10.1038/srep18164. Sci Rep. 2016. PMID: 26750656 Free PMC article. - Long Residence Time at the Neurosteroidogenic 18 kDa Translocator Protein Characterizes the Anxiolytic Ligand XBD173.
Costa B, Da Pozzo E, Cavallini C, Taliani S, Da Settimo F, Martini C. Costa B, et al. ACS Chem Neurosci. 2016 Aug 17;7(8):1041-6. doi: 10.1021/acschemneuro.6b00149. Epub 2016 Jul 8. ACS Chem Neurosci. 2016. PMID: 27385308 - Translocator protein as a promising target for novel anxiolytics.
Costa B, Da Pozzo E, Martini C. Costa B, et al. Curr Top Med Chem. 2012;12(4):270-85. doi: 10.2174/156802612799078720. Curr Top Med Chem. 2012. PMID: 22204481 Review. - Anxiolytics targeting GABAA receptors: Insights on etifoxine.
Poisbeau P, Gazzo G, Calvel L. Poisbeau P, et al. World J Biol Psychiatry. 2018;19(sup1):S36-S45. doi: 10.1080/15622975.2018.1468030. World J Biol Psychiatry. 2018. PMID: 30204559 Review.
Cited by
- Functional role of translocator protein and its ligands in ocular diseases (Review).
Yu M, Zhao S. Yu M, et al. Mol Med Rep. 2024 Feb;29(2):33. doi: 10.3892/mmr.2024.13157. Epub 2024 Jan 8. Mol Med Rep. 2024. PMID: 38186312 Free PMC article. Review. - Short-term effects of etifoxine on human gut microbiome in healthy men.
Manook A, Baghai TC, Riebel M, Nothdurfter C, Schwarzbach JV, Gessner A, Rupprecht R, Hiergeist A. Manook A, et al. Front Neurosci. 2023 Nov 14;17:1188847. doi: 10.3389/fnins.2023.1188847. eCollection 2023. Front Neurosci. 2023. PMID: 38075272 Free PMC article. - Translocator protein in the rise and fall of central nervous system neurons.
Cheung G, Lin YC, Papadopoulos V. Cheung G, et al. Front Cell Neurosci. 2023 Jun 21;17:1210205. doi: 10.3389/fncel.2023.1210205. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37416505 Free PMC article. Review. - The 18-kDa Translocator Protein PET Tracers as a Diagnostic Marker for Neuroinflammation: Development and Current Standing.
Singh P, Adhikari A, Singh D, Gond C, Tiwari AK. Singh P, et al. ACS Omega. 2022 Apr 18;7(17):14412-14429. doi: 10.1021/acsomega.2c00588. eCollection 2022 May 3. ACS Omega. 2022. PMID: 35557664 Free PMC article. Review. - Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein.
Owen DR, Phillips A, O'Connor D, Grey G, Aimola L, Nicholas R, Matthews PM. Owen DR, et al. Br J Clin Pharmacol. 2022 Sep;88(9):4230-4236. doi: 10.1111/bcp.15392. Epub 2022 May 20. Br J Clin Pharmacol. 2022. PMID: 35524344 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources